Atomwise

About

Atomwise develops a deep learning platform, leveraging convolutional neural networks to predict the binding affinity of small molecules to proteins – accelerating the identification of potential drug candidates. Their AI superplatform virtually screens trillions of compounds, identifying novel molecules with potential in areas like immune and inflammatory diseases, and has resulted in multiple programs advancing towards clinical development. Notably, Atomwise has partnered with organizations like the National Institutes of Health and has demonstrated success in repurposing existing drugs for new applications, including identifying potential treatments for Ebola and COVID-19.

Focus Areas

Technology Focus